Genmab A/S
GMABNASDAQHealthcare● Active
$25.15
+$0.42(+1.70%)
Market Cap$15.4B
P/E Ratio—
52W High$35.43
52W Low$20.225
Genmab A/S (GMAB) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GMAB · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.72B | $21.53B | $16.47B | $14.51B | $8.42B |
| Cost of Revenue | $0.31B | $0.98B | $0.23B | $0.00B | $0.00B |
| Gross Profit | $3.41B | $20.54B | $16.25B | $14.51B | $8.42B |
| Gross Margin %(computed) | 91.69% | 95.42% | 98.63% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $1.56B | $9.75B | $7.63B | $5.56B | $4.18B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $2.16B | $13.84B | $10.93B | $8.24B | $5.46B |
| Operating Income | $1.25B | $6.70B | $5.32B | $6.27B | $2.95B |
| Operating Margin %(computed) | 33.60% | 31.14% | 32.30% | 43.21% | 35.08% |
| Interest Income | $0.14B | $0.99B | $0.94B | $0.32B | $0.20B |
| Interest Expense | $0.06B | $0.12B | $0.03B | $0.02B | $0.01B |
| Income Before Tax | $1.20B | $9.16B | $5.64B | $6.95B | $3.92B |
| Income Tax Expense | $0.24B | $1.32B | $1.28B | $1.49B | $0.96B |
| Net Income | $0.96B | $7.84B | $4.35B | $5.45B | $2.96B |
| Net Margin %(computed) | 25.89% | 36.44% | 26.42% | 37.59% | 35.13% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.55 | $12.14 | $6.60 | $8.34 | $4.52 |
| Wtd Avg Shares | 0.62B | 0.65B | 0.66B | 0.65B | 0.65B |
| EBITDA | $1.32B | $9.70B | $5.95B | $7.35B | $4.18B |
| EBITDA Margin %(computed) | 35.51% | 45.05% | 36.10% | 50.64% | 49.67% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Genmab A/S data
About Genmab A/S (GMAB) Income Statement
Genmab A/S (GMAB) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, GMAB reported revenue of $3.72B, gross profit of $3.41B (gross margin 91.69%), and net income of $0.96B — a net profit margin of 25.89%.
Frequently asked questions
GMAB · 4 questionsGenmab A/S (GMAB) reported revenue of $3.72B for 2025, down 82.7% year-over-year.
GMAB revenueGMAB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08